2m 2m 2m 2m 2m 2m 2m
Aclaris Therap (ACRS)
NASDAQ
$4.48-$0.15 (-3.26%)
Price as of Jun 03, 2026 7:58 PM EDT- $635.5MMarket Cap
- 214.97%1-Year Change
- BiotechnologyIndustry
Aclaris Therap (ACRS)
$4.48-$0.15 (-3.26%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 1.9M -90.00% | 18.7M -40.09% | 31.2M +5.03% | 29.8M +340.05% | |
Cost of Revenue | 2.1M -25.11% | 2.8M -18.43% | 3.4M -14.91% | 4.0M -14.64% | |
Gross Profit | -219,000 -101.37% | 15.9M -42.76% | 27.8M +8.15% | 25.7M +1,156.30% | |
Sales and Marketing Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -52.6M +56.75% | -33.6M -65.86% | -98.4M +26.44% | -77.8M +77.60% | |
Depreciation and Amortization Expense | 454,000 -43.74% | 807,000 -6.49% | 863,000 +8.28% | 797,000 -13.65% | |
Total Operating Expenses | 84.2M -47.59% | 160.7M +24.92% | 128.6M +7.52% | 119.6M +23.96% | |
Operating Profit | -76.4M -46.19% | -141.9M +45.79% | -97.4M +8.35% | -89.9M +0.15% | |
Interest Income | 7.6M -3.97% | 8.0M N/A | N/A N/A | N/A N/A | |
Interest Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Income and Expense and Net | 7.6M -3.97% | 8.0M N/A | 0 N/A | 0 N/A | |
Total Nonoperating Income and Expense | 11.5M +16.06% | 9.9M +15.96% | 8.5M +188.83% | 2.9M +357.97% | |
Income before Taxes | -76.4M -42.17% | -132.1M +48.64% | -88.8M +2.23% | -86.9M -4.35% | |
Income Taxes | N/A N/A | -367,000 0.00% | -367,000 +101.65% | -182,000 0.00% | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -64.9M -50.84% | -132.1M +49.26% | -88.5M +1.81% | -86.9M -4.35% | |
Net Income from Continuing Operations Applicable to Common | -64.9M -50.84% | -132.1M +48.64% | -88.8M +2.23% | -86.9M -4.35% | |
Basic EPS and Net Income | -0.53 -69.01% | -1.71 +34.65% | -1.27 -4.51% | -1.33 -16.87% | |
Diluted EPS and Net Income | -0.53 -69.01% | -1.71 +34.65% | -1.27 -4.51% | -1.33 -16.87% | |
Basic Weighted Average Shares | 122.6M +58.56% | 77.3M +10.73% | 69.8M +7.05% | 65.2M +14.95% | |
Diluted Weighted Average Shares | 122.6M +58.56% | 77.3M +10.73% | 69.8M +7.05% | 65.2M +14.95% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 20.0M -18.76% | 24.6M -38.39% | 39.9M -11.92% | 45.3M +65.55% | |
Short-Term Investments | 70.8M -20.48% | 89.0M +12.36% | 79.2M -54.02% | 172.3M +5.02% | |
Cash and Cash Equivalents and Short-Term Investments | 90.8M -20.11% | 113.6M -4.63% | 119.1M -45.26% | 217.6M +13.67% | |
Total Current Assets | 96.3M -23.53% | 126.0M -2.25% | 128.9M -44.35% | 231.6M +12.93% | |
Accumulated Depreciation | N/A N/A | 4.8M +15.45% | 4.2M +3.15% | 4.0M +18.92% | |
Property and Plant and Equipment and Net | 761,000 -24.50% | 1.0M -37.78% | 1.6M +47.41% | 1.1M -17.68% | |
Total Long-Term Assets | 2.8M -9.62% | 3.1M -21.16% | 3.9M +42.35% | 2.7M -23.13% | |
Total Assets | 160.5M -27.17% | 220.3M +11.61% | 197.4M -22.46% | 254.6M +1.35% | |
Income Taxes Payable | N/A N/A | N/A N/A | 367,000 0.00% | 367,000 0.00% | |
Total Short-Term Debt | N/A N/A | N/A N/A | 11.0M 0.00% | 11.0M 0.00% | |
Total Current Liabilities | 28.6M -9.34% | 31.6M +2.08% | 31.0M +41.09% | 21.9M -4.33% | |
Total Long-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Long-Term Liabilities | 1.6M -64.74% | 4.4M +44.40% | 3.1M +95.80% | 1.6M -27.72% | |
Total Liabilities | 57.4M -11.42% | 64.8M +61.02% | 40.2M -29.40% | 57.0M +5.76% | |
Retained Earnings | -967.8M +7.19% | -902.9M +17.13% | -770.8M +12.97% | -682.3M +14.60% | |
Total Stockholders Equity | 103.1M -33.73% | 155.6M -1.03% | 157.2M -20.46% | 197.6M +0.14% | |
Total Shares Outstanding | 120.5M +11.73% | 107.9M +52.13% | 70.9M +6.31% | 66.7M +8.92% | |
Cash Flow | |||||
Cash from Operating Activities | -47.1M +134.68% | -20.1M -74.37% | -78.3M +15.92% | -67.6M +29.60% | |
Capital Expenditures | 111,000 -8.26% | 121,000 -90.76% | 1.3M +116.36% | 605,000 +96.43% | |
Cash from Investing Activities | 48.4M +169.32% | -69.8M -250.95% | 46.2M +266.01% | 12.6M +107.53% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | -5.9M -107.86% | 74.5M +179.10% | 26.7M -63.35% | 72.9M -67.62% | |
Financials Ratio | |||||
Gross Margin | -11.70% -113.75% | 85.09% -4.45% | 89.05% +2.97% | 86.48% +185.49% | |
Operating Margin | -4,079.86% +438.11% | -758.18% +143.36% | -311.55% +3.16% | -302.01% -77.24% | |
Return on Assets | -34.10% -46.07% | -63.23% +61.50% | -39.15% +13.93% | -34.36% -39.11% | |
Return on Equity | -50.20% -40.56% | -84.46% +69.34% | -49.88% +13.33% | -44.01% -43.09% | |
Revenue Growth | -90.00% +124.47% | -40.09% -896.85% | 5.03% -98.52% | 340.05% +7,800.50% | |
Current Ratio | 3.36 -15.65% | 3.99 -4.25% | 4.16 -60.56% | 10.55 +18.04% | |
Cash Ratio | 0.70 -10.39% | 0.78 -39.65% | 1.29 -37.57% | 2.06 +73.04% | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow